ReviewMolecular genetics & genomic medicine2026
PDXK-Related Neuropathy: A Case With a Novel Splice-Altering Missense Variant and Literature Review.
Review in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPDXK-related neuropathy is a rare form of hereditary motor and sensory neuropathy with optic atrophy, caused by biallelic variants in the PDXK gene. To date, only four missense variants have been reported in 13 patients from six families. Unlike most inherited neuropathies, which currently have only symptomatic treatments, this type of neuropathy can be managed with pyridoxal 5'-phosphate supplementation.
methodsThe clinical presentation of the patient was evaluated twice, at ages 14 and 15 years. The whole-exome sequencing was performed for the proband followed by functional studies using RNA extracted from the proband's and proband's mother's peripheral blood mononuclear cells.
resultsIn this study, we provided a brief literature review on PDXK-related neuropathy and reported a female patient with a novel missense variant (c.826G>C, p.(Ala276Pro)) found in compound heterozygous state with a previously reported variant (c.659G>A, p.[Arg220Gln]) in the PDXK gene. Additionally, she carried a novel likely pathogenic missense variant (c.1180C>T, p.[Arg394Cys]) in the GCK gene, associated with MODY2, which was segregated with hyperglycemia in her family. The novel variant c.826G>C in the PDXK gene was predicted to disrupt splicing that was confirmed by our functional studies. The patient exhibited typical peripheral neuropathy but no optic atrophy, likely due to her young age.
conclusionsHere we report a novel splice-altering missense variant in PDXK that induces aberrant transcript degradation, revealing a new disease mechanism for PDXK-related neuropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.